NCT00979004View on ClinicalTrials.gov

A Study to Investigate the Effect of ICA-105665 in Photosensitive Epilepsy Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Epilepsy
Interventions
DRUG

ICA-105665

Oral tablet. Dose forms of 50 and 100 mg or placebo will be used. A single dose will be administered that can range from placebo or 100 to 600 mg.

Trial Locations (3)

37232

Pfizer Investigational Site, Nashville

63017

Pfizer Investigational Site, Chesterfield

72205

Pfizer Investigational Site, Little Rock

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00979004 - A Study to Investigate the Effect of ICA-105665 in Photosensitive Epilepsy Patients | Biotech Hunter | Biotech Hunter